According to Bristol-Myers Squibb's latest financial reports the company has a price-to-book ratio of 3.32.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 3.54 | -27.97% |
2022-12-31 | 4.92 | 27.9% |
2021-12-31 | 3.84 | 3.88% |
2020-12-31 | 3.70 | 33.76% |
2019-12-31 | 2.77 | -53.7% |
2018-12-31 | 5.98 | -29.42% |
2017-12-31 | 8.47 | 41.7% |
2016-12-31 | 5.97 | -24.58% |
2015-12-31 | 7.92 | 21.64% |
2014-12-31 | 6.51 | 13.76% |
2013-12-31 | 5.72 | 46.97% |
2012-12-31 | 3.90 | 3.5% |
2011-12-31 | 3.76 | 30.82% |
2010-12-31 | 2.88 | -1.43% |
2009-12-31 | 2.92 | -22.59% |
2008-12-31 | 3.77 | -23.94% |
2007-12-31 | 4.96 | -4.1% |
2006-12-31 | 5.17 | 28.81% |
2005-12-31 | 4.01 | -17.94% |
2004-12-31 | 4.89 | -13.76% |
2003-12-31 | 5.67 | 9.77% |
2002-12-31 | 5.17 |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
Johnson & Johnson JNJ | 5.11 | 53.81% | ๐บ๐ธ USA |
Novartis NVS | 4.05 | 21.91% | ๐จ๐ญ Switzerland |
Pfizer PFE | 1.61 | -51.50% | ๐บ๐ธ USA |
AbbVie ABBV | 28.0 | 744.62% | ๐บ๐ธ USA |
Eli Lilly LLY | 65.3 | 1,866.33% | ๐บ๐ธ USA |
Amgen AMGN | 22.6 | 580.56% | ๐บ๐ธ USA |
Sanofi SNY | 1.38 | -58.48% | ๐ซ๐ท France |
Biogen BIIB | 1.87 | -43.64% | ๐บ๐ธ USA |
Merck MRK | 8.43 | 153.87% | ๐บ๐ธ USA |
AstraZeneca AZN | 5.41 | 62.99% | ๐ฌ๐ง UK |